A a study that examined varenicline has found that it is a safe and effective treatment for smoking cessation in smokers with cardiovascular disease.
Researchers conducted a multicentre, randomized, double-blind, placebo-controlled trial to compare the efficacy and safety of varenicline with a placebo for smoking cessation. The study included 714 smokers with stable cardiovascular disease.
Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counselling, for 12 weeks and were followed up for 52 weeks.
The researchers found that smoking cessation was more effective with varenicline than placebo. The two groups did not differ significantly in cardiovascular mortality or cardiovascular events.
The authors note that the size of the trial and duration limit any definitive conclusions about safety.